CYNO Cynosure - Class A (MM)

WESTFORD, Mass., Jan. 17 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced it has received Class III medical device license approval from Health Canada to market and sell its flagship Affirm(TM) laser system in Canada. The Affirm system is a single platform, multi-energy technology designed for anti-aging applications, including skin rejuvenation and treatments for wrinkles, skin texture and discoloration. The Affirm system features Cynosure's proprietary Combined Apex Pulse(SM) (CAP) technology, a disposable microlens array for reducing the appearance of wrinkles and scars with micro- rejuvenation capabilities to create a more complete skin treatment. The precision of the CAP technology allows providers to treat patients more rapidly and with greater comfort than other products available on the market today. "We are delighted to be able to offer the Affirm system, and our unique approach to skin revitalization, to the Canadian market as a result of the Health Canada clearance," said Michael R. Davin, CEO of Cynosure, Inc. "Reaction to the Affirm workstation from aesthetic professionals and their patients continues to be positive. With its single platform and multi-energy technology structure, we believe the Affirm will continue to help us address the emerging skin rejuvenation market." Brian Biesman, M.D., medical director for the Nashville Centre for Laser and Facial Surgery, commented, "I use the Affirm to treat a wide range of skin conditions, from mild-to-moderate photo-aging and brown discoloration to mild- to-moderate wrinkles and surgical scars, on the face, neck, chest and hands. We've seen excellent results in these areas, and patient feedback has been very favorable." Sherry Collawn, M.D., clinical professor of plastic surgery, University of Alabama, said, "The majority of my patients choose the Affirm laser for its easy treatments and better results, particularly with wrinkles, than competing products. We have found that optimal results typically occur several months after treatment, though some of our patients have experienced a measurable improvement in as little as one week." About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, remove unwanted fat and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com/. Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the future use and market acceptance of the Affirm system, the markets in which Cynosure's products are sold, and other statements containing the words "believes," "anticipates," "plans," "expects," "will," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our history of operating losses, our reliance on sole source suppliers, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's Annual Report on Form 10-K filed with the SEC. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President of Sharon Merrill Associates, Inc., +1-617-542-5300, or , for Cynosure, Inc. Web site: http://www.cynosurelaser.com/

Copyright